Before you sell to, join or invest in Aclaris Therapeutics, Inc.
MentionFox check on Aclaris Therapeutics, Inc.: only 1 source on file so far (checked 8 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/aclaris-therapeutics-inc-form-d-24000001
Check Aclaris Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Aclaris Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2024-12-04.
Aclaris Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 4, 2024. The filing reports $80M sold. Its industry group is Pharmaceuticals. It names Neal Walker (Executive Officer, Director), Hugh Davis (Executive Officer, Director), Kevin Balthaser (Executive Officer) (SEC Form D, December 4, 2024).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Aclaris Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-12-04 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Aclaris Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Aclaris Therapeutics, Inc., from the filings we hold.
Leerink Partners LLC received sales compensation on this raise and on 16 other raises we hold, nearest in date first:
Cantor Fitzgerald & Co. received sales compensation on this raise and on 8 other raises we hold, nearest in date first:
Get an email when Aclaris Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Aclaris Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Aclaris Therapeutics, Inc. →Get the full cited report on Aclaris Therapeutics, Inc.
What the filing shows about Aclaris Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aclaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Aclaris Therapeutics, Inc.'s address as 701 Lee Road, Suite 103, Wayne, PA 19087.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Aclaris Therapeutics, Inc. See pricing
Aclaris Therapeutics, Inc. is a registered filer with the SEC (CIK 1557746) and has filed since 2024-12-04. 1 filing is on record, the latest on 2024-12-04.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Aclaris Therapeutics, Inc.'s Form D of 2024-12-04 names Neal Walker, Hugh Davis, Kevin Balthaser and 8 more as its officers, directors or promoters.
Its new offerings report $80M sold across 1 offering, as its own filings state.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Neal Walker is named as Executive Officer and Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Hugh Davis is named as Executive Officer and Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Kevin Balthaser is named as Executive Officer on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
James Loerop is named as Executive Officer on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Joseph Monahan is named as Executive Officer on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Maxine Gowen is named as Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
William Humphries is named as Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Anand Mehra is named as Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Vincent Milano is named as Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Christopher Molineaux is named as Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
Andrew Schiff is named as Director on the Form D that Aclaris Therapeutics, Inc. filed with the SEC on 4 December 2024, one of 11 people that filing names.
11 people named on the filing — 5 holding an executive role and 6 as directors only.
Named as of the 2024-12-04 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Aclaris Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aclaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aclaris Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aclaris Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Aclaris Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Aclaris Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/aclaris-therapeutics-inc-form-d-24000001